Top news of the week: 15.09.2021.
Companies And Industries
Clinical Catch-Up: September 6-10
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
CureVac Adjusts to Vaccine Demand by Reducing European mRNA Manufacturing Network
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
RedHill BioPharma follows familiar biotech path after COVID-19 drug fails in severe patients
RedHill Biopharma has rolled snake eyes in a late-stage trial for its experimental COVID-19 treatment, the SK2 inhibitor opaganib, which has failed to help severely ill patients.
AzurRx Carves Out Slice of IBD Market in $229 Million Buyout
AzurRx will change its name to First Wave BioPharma, Inc., and the company’s shares will trade on the Nasdaq under the ticker symbol “FWBI.”
Biobot Analytics Demonstrates the Utility of Wastewater Sequencing As a Powerful Tool in the Fight Against COVID-19 Variants
Cambridge, Mass. – September 9th, 2021 – Biobot Analytics, in collaboration with Ginkgo Bioworks, today announced a successful campaign to sequence over 2,000 wastewater samples across all ...
iECURE emerges with $50M to search for 'holy grail' and 'untapped frontier' of gene editing
iECURE is emerging from stealth with $50 million and a mission to go after the "holy grail" of gene editing with an in vivo approach that is mutation agnostic. The biotech will use the ...
EU ‘negotiating with Valneva’ over COVID-19 vaccine contract
UK Health Secretary Sajid Javid claims MHRA would not approve Valneva's COVID-19 vaccine, as reports suggest the European Commission is looking at using the shot in booster plans
Could This Drug Delivery Capsule Replace Injections?
Antibodies are naturally produced by many organisms, as part of immune defense. They also have potential as a therapeutic. | Cell And Molecular Biology